| AbbVie AG - Skyrizi 75 mg, lnjektionslösung in einer Fertigspritze |
| 66944 | | 01 | | Skyrizi 75 mg | | lnjektionslösung in einer Fertigspritze | | L04AC18 | | Risankizumab | | 18.04.2019 | | |
|
| Composition |
| Lösung: risankizumabum 75.0 mg, sorbitolum 34 mg, dinatrii succinas hexahydricus corresp. natrium 0.149 mg, natrium 0.149 mg, acidum succinicum, polysorbatum 20, aqua ad iniectabile ad solutionem pro 0.83 ml.
Tela cum: alcohol isopropylicus. |
| Packungsbestandteile |
| lnjektionslösung | | | | | | BAG: Active Agent | Dose |
|---|
| Risankizumabum | 75 mg |
| | | | Inactive agents | | additional_information |
|---|
| Alcohol Isopropylicus | | Tela cum |
| |
| lnjektionslösung in einer Fertigspritze | | | | | | | | Active Agent | Dose | additional_information |
|---|
| Risankizumabum | 75mg / 0.83ml | Lösung |
| | BAG: Active Agent | Dose |
|---|
| Risankizumabum | 75 mg |
| | | | Inactive agents | Dose |
|---|
| Succinic Acid | | | Dinatrii Succinas Hexahydricus | | | Sodium | 0.149mg / 0.83ml | | Polysorbatum 20 | | | Sorbitol | 34mg / 0.83ml |
| |
|
| Package number | Package Size | EFP | CP | Category | SL | Out of trade (MedRef) |
|---|
| 001 | 2 | 3293.76 | 3622.10 | B | | Yes |
|
